Interventional device developer Abbott Vascular Devices has introduced its TriMaxx coronary stent, as well as six other interventional cardiovascular products in Europe.
TriMaxx, which also serves as the platform for Abbott's ZoMaxx investigational drug-eluting stent, features mesh scaffolding and a low crossing profile designed to facilitate stent placement in arteries, according to the subsidiary of Abbott Laboratories of Abbott Park, IL. It's available in Europe at sizes ranging from 2.25 mm to 4.0 mm, and lengths ranging from 8 mm to 28 mm.
In other European launches, Abbott has introduced a noncompliant Mercury coronary balloon catheter for high-pressure postdilation of coronary stents; the Xceed vascular nitinol self-expanding stent; the Xpert vascular self-expanding stent; and the Fox Plus and Fox sv PTA catheters.
The firm said it has enrolled the first patient in its ZoMaxx II North American drug-eluting coronary stent clinical trial.
By AuntMinnie.com staff writers
May 25, 2005
Related Reading
Abbott submits StarClose PMA, April 13, 2005
Abbott gets FDA OK for ZoMaxx trial, April 7, 2005
Abbott to launch carotid stent trial, January 20, 2005
Abbott plans drug-eluting stent trial, September 28, 2004
Abbott starts ZoMaxx stent trial, September 17, 2004
Copyright © 2005 AuntMinnie.com
